NCT02640170

Brief Summary

The purpose of this registry is to monitor the rate of recurrence in patients who undergo cancer surgery.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
291

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jul 2016

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 22, 2015

Completed
6 days until next milestone

First Posted

Study publicly available on registry

December 28, 2015

Completed
6 months until next milestone

Study Start

First participant enrolled

July 1, 2016

Completed
3.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2020

Completed
Last Updated

June 24, 2021

Status Verified

June 1, 2021

Enrollment Period

3.6 years

First QC Date

December 22, 2015

Last Update Submit

June 21, 2021

Conditions

Lung Nodule, Breast, Kidney,Parathyroid, Mediastinal, Skin Mass, Soft Tissue, Prostate, Stomach Pleural, Head and Neck, and Are at Risk of Recurrence

Outcome Measures

Primary Outcomes (1)

  • Number of subjects registered

    2 years

Interventions

RegistryOTHER

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Patients with a diagnosis of any resectable solid tumor, including but not limited to lung nodule, breast, kidney,parathyroid, mediastinal, skin mass, soft tissue, prostate, stomach pleural, head and neck, and are at risk of recurrence

You may qualify if:

  • Inclkusion Criteria
  • Adult patients \>= 18 years of age
  • Patients presenting with any solid tumor and/or diseased tissue even benign nodules presumed to be resectable and are at risk for recurrence.
  • Good operative candidate as determined by the treating physician and/or multidisciplinary team
  • Subject capable of giving informed consent and participating in the process of consent.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Abramson Cancer Center of the University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States

Location

Related Publications (1)

  • Newton AD, Predina JD, Corbett CJ, Frenzel-Sulyok LG, Xia L, Petersson EJ, Tsourkas A, Nie S, Delikatny EJ, Singhal S. Optimization of Second Window Indocyanine Green for Intraoperative Near-Infrared Imaging of Thoracic Malignancy. J Am Coll Surg. 2019 Feb;228(2):188-197. doi: 10.1016/j.jamcollsurg.2018.11.003. Epub 2018 Nov 22.

    PMID: 30471345DERIVED

MeSH Terms

Interventions

Registries

Intervention Hierarchy (Ancestors)

Data CollectionEpidemiologic MethodsInvestigative TechniquesRecordsOrganization and AdministrationHealth Services AdministrationHealth Care Evaluation MechanismsQuality of Health CareHealth Care Quality, Access, and EvaluationPublic HealthEnvironment and Public Health

Study Officials

  • Sunil Singhal, MD, PhD

    Abramson Cancer Center at Penn Medicine

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
30 Days
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 22, 2015

First Posted

December 28, 2015

Study Start

July 1, 2016

Primary Completion

February 1, 2020

Study Completion

February 1, 2020

Last Updated

June 24, 2021

Record last verified: 2021-06

Locations

US(1)